Kaposi's Sarcoma & HIV/AIDS: Research
- UCSF Researchers Identify New Drug Target for Kaposi's Sarcoma (July 29, 2009)
Researchers believe that engineering a new type of protease inhibitor could prove to be an effective form of KS treatment.
From University of California-San Francisco
- Early KS Can Be Successfully Treated With HIV Treatment and No Need for Chemotherapy (April 7, 2009)
From aidsmap.com
- Peculiar Type of KS Emerges in Healthier Individuals (November 7, 2008)
From Project Inform
- New Type of Kaposi?s Sarcoma Seen in HIV-Negative Gay Men (June 18, 2008)
From aidsmap.com
- Scoring Tool Predicts Risk of KS Progression (June 12, 2008)
In aidsmap.com
- Physicians in S.F. Identify Kaposi's Sarcoma Cluster Among HIV-Infected MSM (October 15, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Incidence of AIDS-Associated and Non-AIDS-Associated Malignancies Among HIV-Infected Individuals (February 6, 2006)
Recent studies examine the risks for Kaposi's sarcoma, non-Hodgkin's lymphoma, cervical cancer, lung cancer and other malignancies.
In The 13th Conference on Retroviruses and Opportunistic Infections
- Human Herpesvirus-8, Kaposi Sarcoma, and AIDS-Associated Neoplasms (January 2006)
A clinical overview from the comprehensive, online textbook of HIV disease from the University of California San Francisco and San Francisco General Hospital.
From HIV InSite
- HAART May Need Help to Treat Severe Kaposi's Sarcoma, Study Suggests (August 20, 2004)
For those with moderate to severe KS, chemotherapy plus HAART is found to work better than HAART alone, in contradiction to earlier studies.
From aidsmap.com
- New Discovery on Kaposi's Sarcoma May Yield Better Testing, Treatment (June 28, 2004)
British scientists say they have finally discovered the location within the human immune system where Kaposi's sarcoma first develops.
From Agence de Presse Medicale
- 4th International AIDS Malignancy Conference (May 16-18, 2000)
In The 4th International AIDS Malignancy Conference, from The Body PRO
|
|
Advertisement
|